JAMES A. JOHNSON - 20 May 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Director
Signature
/s/ Glenna Mileson, attorney-in-fact on behalf of James A. Johnson
Issuer symbol
ATHA
Transactions as of
20 May 2022
Net transactions value
$0
Form type
4
Filing time
27 May 2022, 17:40:34 UTC
Previous filing
01 Jun 2021
Next filing
30 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +13,871 $0.000000 13,871 20 May 2022 Common Stock 13,871 $8.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy.